Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Price & Overview
NASDAQ:CTNM • US21217B1008
Current stock price
12.83 USD
+0.79 (+6.56%)
Last:
The current stock price of CTNM is 12.83 USD. Today CTNM is up by 6.56%. In the past month the price decreased by -7.81%. In the past year, price increased by 193.66%.
CTNM Key Statistics
52-Week Range3.35 - 16.33
Current CTNM stock price positioned within its 52-week range.
1-Month Range11.81 - 14.055
Current CTNM stock price positioned within its 1-month range.
- Market Cap
- 479.072M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.18
- Dividend Yield
- N/A
CTNM Stock Performance
Today
+6.56%
1 Week
-7.10%
1 Month
-7.81%
3 Months
-15.57%
Longer-term
6 Months +9.36%
1 Year +193.66%
2 Years -22.82%
3 Years N/A
5 Years N/A
10 Years N/A
CTNM Stock Chart
CTNM Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CTNM. When comparing the yearly performance of all stocks, CTNM is one of the better performing stocks in the market, outperforming 95.55% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CTNM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTNM. While CTNM has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CTNM Earnings
Next Earnings DateMay 14, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.49
Revenue Reported
EPS Surprise -18.41%
Revenue Surprise -100.00%
CTNM Forecast & Estimates
13 analysts have analysed CTNM and the average price target is 22.44 USD. This implies a price increase of 74.9% is expected in the next year compared to the current price of 12.83.
Analysts
Analysts86.15
Price Target22.44 (74.9%)
EPS Next Y3.82%
Revenue Next YearN/A
CTNM Index Membership
CTNM is currently included in the following stock indexes tracked on ChartMill.
CTNM Financial Highlights
Over the last trailing twelve months CTNM reported a non-GAAP Earnings per Share(EPS) of -2.18. The EPS increased by 55.51% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-56.86M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.09% | ||
| ROE | -33.18% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%12.5%
Sales Q2Q%N/A
EPS 1Y (TTM)55.51%
Revenue 1Y (TTM)N/A
CTNM Ownership
Ownership
Inst Owners86.2%
Shares37.34M
Float30.88M
Ins Owners1.01%
Short Float %10.04%
Short Ratio10.59
CTNM Industry Overview
CTNM operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
35%
Outperformed 35% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 3.7%
- New Lows
- 4.4%
- Average ROE
- 50.3%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.4%
- Average P/E
- 26.1
- Average Fwd P/E
- 20.5
- Average Debt/Equity
- 1.2
CTNM Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.91 | 804.24B | ||
| JNJ | JOHNSON & JOHNSON | 18.1 | 547.597B | ||
| MRK | MERCK & CO. INC. | 21.63 | 274.033B | ||
| PFE | PFIZER INC | 8.92 | 149.376B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.48 | 117.584B | ||
| ZTS | ZOETIS INC | 16.17 | 47.868B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.61 | 28.553B | ||
| VTRS | VIATRIS INC | 6.05 | 17.431B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.09 | 10.887B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.409B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.108B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.796B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.01 | 4.956B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CTNM
Company Profile
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2024-04-05. The company is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The firm is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Company Info
IPO: 2024-04-05
CONTINEUM THERAPEUTICS INC-A
3565 General Atomics Court, Suite 200
San Diego CALIFORNIA US
Employees: 51
Phone: 18583335280
CONTINEUM THERAPEUTICS INC-A / CTNM FAQ
What does CONTINEUM THERAPEUTICS INC-A do?
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2024-04-05. The company is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The firm is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
What is the current price of CTNM stock?
The current stock price of CTNM is 12.83 USD. The price increased by 6.56% in the last trading session.
Does CTNM stock pay dividends?
CTNM does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTNM stock?
CTNM has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy CTNM stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CTNM.
Can you provide the ownership details for CTNM stock?
You can find the ownership structure of CONTINEUM THERAPEUTICS INC-A (CTNM) on the Ownership tab.
What is the outstanding short interest for CONTINEUM THERAPEUTICS INC-A?
The outstanding short interest for CONTINEUM THERAPEUTICS INC-A (CTNM) is 10.04% of its float.